| Phase I trials of targeted anticancer drugs: a need to refocus. | |
| | |
MedLine Citation:
|
PMID: 23197020 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies. |
| | |
Authors:
|
Ernest C Borden; Afshin Dowlati |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: 11 ISSN: 1474-1784 ISO Abbreviation: Nat Rev Drug Discov Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: England |
Other Details:
|
Languages: eng Pagination: 889-90 Citation Subset: IM |
Affiliation:
|
Case Comprehensive Cancer Center, Taussig Cancer Institute R40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reflections on my Family History, my Youth, and my Professional Career.
Next Document: Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.